Suppr超能文献

肉瘤样反应:恶性黑色素瘤免疫治疗的独特反应。

Sarcoid-like reaction: a unique response to immunotherapy in malignant melanoma.

机构信息

Oncology, Sligo University Hospital, Sligo, Ireland

Oncology, Sligo University Hospital, Sligo, Ireland.

出版信息

BMJ Case Rep. 2021 May 28;14(5):e243723. doi: 10.1136/bcr-2021-243723.

Abstract

In recent years, immunotherapy has revolutionised the treatment landscape for oncology patients with improved survival rates in cancers which previously had a dismissal prognosis. These agents target specific pathways of inhibition such as programmed cell death -1 (PD-1), PD ligand-1 and cytotoxic T-lymphocyte-associated antigen 4 resulting in stimulation of T cell activity. This results in enabling an individual's own immune system to fight against cancer, a different modality of treatment when compared with traditional chemotherapy. While attacking the tumour cells, there is an increased chance of host tissue immune reactions.We report a case of a patient who received immunotherapy for metastatic malignant melanoma. During the course of the treatment, development of a sarcoid-like reaction was histologically confirmed in the mediastinal lymph nodes. The patient had no respiratory symptoms and continued on the immunotherapy treatment with good clinical and radiological response.

摘要

近年来,免疫疗法彻底改变了肿瘤患者的治疗前景,提高了以往预后不佳的癌症患者的生存率。这些药物针对特定的抑制途径,如程序性细胞死亡蛋白 1(PD-1)、PD 配体-1 和细胞毒性 T 淋巴细胞相关抗原 4,从而刺激 T 细胞活性。这使得个体自身的免疫系统能够对抗癌症,与传统化疗相比是一种不同的治疗模式。在攻击肿瘤细胞的同时,宿主组织免疫反应的机会增加。我们报告了一例接受免疫治疗转移性恶性黑色素瘤的患者。在治疗过程中,纵隔淋巴结的组织学证实发生了类肉瘤样反应。患者无呼吸症状,并继续接受免疫治疗,临床和影像学反应良好。

相似文献

1
Sarcoid-like reaction: a unique response to immunotherapy in malignant melanoma.
BMJ Case Rep. 2021 May 28;14(5):e243723. doi: 10.1136/bcr-2021-243723.
2
Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
Eur J Cancer. 2020 May;131:18-26. doi: 10.1016/j.ejca.2020.02.024. Epub 2020 Apr 2.
3
Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma.
Chest. 2016 May;149(5):e133-6. doi: 10.1016/j.chest.2015.10.082.
6
Immunotherapy of patients with metastatic melanoma.
Chin Clin Oncol. 2017 Apr;6(2):20. doi: 10.21037/cco.2017.04.01.
7
Immunotherapy in melanoma: Recent advances and future directions.
Eur J Surg Oncol. 2017 Mar;43(3):604-611. doi: 10.1016/j.ejso.2016.07.145. Epub 2016 Sep 2.
9
Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors.
J Oncol Pharm Pract. 2017 Dec;23(8):620-624. doi: 10.1177/1078155216667635. Epub 2016 Sep 2.

引用本文的文献

本文引用的文献

2
Pembrolizumab-induced Sarcoid-like Reactions during Treatment of Metastatic Melanoma.
Radiology. 2018 Nov;289(2):564-567. doi: 10.1148/radiol.2018180572. Epub 2018 Aug 14.
3
Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors.
J Thorac Oncol. 2018 Aug;13(8):1076-1082. doi: 10.1016/j.jtho.2018.04.031. Epub 2018 May 12.
4
The Balance of Th17 versus Treg Cells in Autoimmunity.
Int J Mol Sci. 2018 Mar 3;19(3):730. doi: 10.3390/ijms19030730.
5
Sarcoid-like reactions in patients receiving modern melanoma treatment.
Melanoma Res. 2018 Jun;28(3):230-236. doi: 10.1097/CMR.0000000000000437.
6
Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Oncologist. 2016 Oct;21(10):1230-1240. doi: 10.1634/theoncologist.2016-0055. Epub 2016 Jul 8.
7
Nivolumab in previously untreated melanoma without BRAF mutation.
N Engl J Med. 2015 Jan 22;372(4):320-30. doi: 10.1056/NEJMoa1412082. Epub 2014 Nov 16.
8
Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity.
Am J Respir Crit Care Med. 2014 Sep 1;190(5):560-71. doi: 10.1164/rccm.201401-0188OC.
9
Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.
J Immunother. 2012 Jan;35(1):89-97. doi: 10.1097/CJI.0b013e31823aa41c.
10
CTLA4 blockade increases Th17 cells in patients with metastatic melanoma.
J Transl Med. 2009 May 20;7:35. doi: 10.1186/1479-5876-7-35.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验